Date: 2016-09-07
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the 6th European Workshop on Lipid Mediators, 6EWLM
Company: Probiodrug (Germany)
Product: PQ912
Action
mechanism:
- glutaminyl cyclase inhibitor/enzyme inhibitor. PQ912 is a small molecule that targets glutaminyl cyclase, an enzyme that catalyzes the formation of pyroGlu amyloid-beta (ABeta) a highly toxic ABeta variant that is involved in the development and progression of Alzheimer disease. This neurodegenerative disease is characterized by deposits of extracellular ABeta plaques in the brain, intraneuronal tangles and cerebral neuronal loss. QC inhibitors address a major pathology associated with AD by inhibiting the formation of ABeta variants which lead to the assembly of highly neurotoxic ABeta-oligomers. PQ912 is a glutaminyl cyclase (QC) inhibitor for the treatment of Alzheimer disease and it is the first QC inhibitor to enter clinical development.
Disease:
Therapeutic
area: Inflammatory diseases
Country:
Trial
details:
Latest
news:
- • On September 7, 2016, Probiodrug announced new findings for its Glutaminyl Cyclase (QC) inhibitor in an inflammation animal model. Data were generated in collaboration with Ambiotis SAS (Toulouse, France) and will be presented at upcoming scientific conferences. The effect of the QC inhibitor PQ912 was investigated in a mouse model of inflammation (thioglycollate induced peritonitis) with special focus on its effect on cell infiltration and release of pro-resolving lipid mediators. The effects seen with PQ912 on recruitment of macrophages and eosinophils, and levels of chemokines and lipid mediators, makes QC inhibition attractive for further evaluation as potential anti-inflammatory drug and/or resolution promoting agent. Data will be summarized as a poster entitled “Glutaminyl cylase (QC) inhibition in a mouse peritonitis model effects eosinophil and macrophage recruitment and levels of resolution molecules” and presented at the Summer Frontiers Symposium 2016 ‘Systems Biology of Innate Immunity’ and at the 6th European Workshop on Lipid Mediators, 6EWLM (poster 34). Commenting on the announcement, Dr Inge Lues, CDO of Probiodrug said: “The results obtained to elucidate molecular mechanisms underlying inflammatory disease, triggered by the innate immune system, further the concept of an anti-inflammatory component of QC inhibition, which might play a role in various diseases with an inflammatory component.”
Is
general: Yes
